Limits...
Emerging approaches of transcatheter valve repair/insertion.

Taramasso M, Cioni M, Giacomini A, Michev I, Godino C, Montorfano M, Colombo A, Alfieri O, Maisano F - Cardiol Res Pract (2010)

Bottom Line: Aortic stenosis (AS) and mitral regurgitation (MR) account for the majority of valvular diseases and their prevalence is increasing according to increased life expectancy.A large part of the patients at high surgical risk who could beneficiate of treatment are not referred to surgery.Therefore, there is a need of alternative and less invasive procedures.

View Article: PubMed Central - PubMed

Affiliation: Cardiothoracic Department, San Raffaele Scientific Institute, via Olgettina 60, 20122 Milan, Italy.

ABSTRACT
Aortic stenosis (AS) and mitral regurgitation (MR) account for the majority of valvular diseases and their prevalence is increasing according to increased life expectancy. Surgical treatment is the gold standard, although operative risk may be high in some patients due to comorbidities and age. A large part of the patients at high surgical risk who could beneficiate of treatment are not referred to surgery. Therefore, there is a need of alternative and less invasive procedures.

No MeSH data available.


Related in: MedlinePlus

The CoreValve self-expandable prosthetic valve, constructed of a nitinol stent, pericardial leaflets, and sealing cuff.
© Copyright Policy - open-access
Related In: Results  -  Collection


getmorefigures.php?uid=PMC2926577&req=5

fig2: The CoreValve self-expandable prosthetic valve, constructed of a nitinol stent, pericardial leaflets, and sealing cuff.

Mentions: The second device is the CoreValve Revalving System (Medtronic, Inc., MN, USA—Figure 2), which consists in three porcine pericardial leaflets mounted in a self-expanding nitinol frame. The CoreValve is available in 26 and 29 mm sizes, going through an 18 F introducer, allowing smaller arterial diameters (6 mm) in respect to the delivery system of the Edwards-Sapien valve. The total length of the valve is 50 mm. It has a specific design with a waist in the middle part. The lower part of the valve is designed to expand using high-radial forces. The middle part includes the leaflets and is constrained to avoid coronary occlusion, while the upper part enables fixation in the ascending aorta. The CoreValve is typically implanted retrograde from the femoral artery.


Emerging approaches of transcatheter valve repair/insertion.

Taramasso M, Cioni M, Giacomini A, Michev I, Godino C, Montorfano M, Colombo A, Alfieri O, Maisano F - Cardiol Res Pract (2010)

The CoreValve self-expandable prosthetic valve, constructed of a nitinol stent, pericardial leaflets, and sealing cuff.
© Copyright Policy - open-access
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC2926577&req=5

fig2: The CoreValve self-expandable prosthetic valve, constructed of a nitinol stent, pericardial leaflets, and sealing cuff.
Mentions: The second device is the CoreValve Revalving System (Medtronic, Inc., MN, USA—Figure 2), which consists in three porcine pericardial leaflets mounted in a self-expanding nitinol frame. The CoreValve is available in 26 and 29 mm sizes, going through an 18 F introducer, allowing smaller arterial diameters (6 mm) in respect to the delivery system of the Edwards-Sapien valve. The total length of the valve is 50 mm. It has a specific design with a waist in the middle part. The lower part of the valve is designed to expand using high-radial forces. The middle part includes the leaflets and is constrained to avoid coronary occlusion, while the upper part enables fixation in the ascending aorta. The CoreValve is typically implanted retrograde from the femoral artery.

Bottom Line: Aortic stenosis (AS) and mitral regurgitation (MR) account for the majority of valvular diseases and their prevalence is increasing according to increased life expectancy.A large part of the patients at high surgical risk who could beneficiate of treatment are not referred to surgery.Therefore, there is a need of alternative and less invasive procedures.

View Article: PubMed Central - PubMed

Affiliation: Cardiothoracic Department, San Raffaele Scientific Institute, via Olgettina 60, 20122 Milan, Italy.

ABSTRACT
Aortic stenosis (AS) and mitral regurgitation (MR) account for the majority of valvular diseases and their prevalence is increasing according to increased life expectancy. Surgical treatment is the gold standard, although operative risk may be high in some patients due to comorbidities and age. A large part of the patients at high surgical risk who could beneficiate of treatment are not referred to surgery. Therefore, there is a need of alternative and less invasive procedures.

No MeSH data available.


Related in: MedlinePlus